Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

OBJECTIVE: To evaluate the long‐term safety and tolerability of ubrogepant for the acute treatment of migraine. BACKGROUND: Ubrogepant is an oral, calcitonin gene–related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Ailani, Jessica, Lipton, Richard B., Hutchinson, Susan, Knievel, Kerry, Lu, Kaifeng, Butler, Matthew, Yu, Sung Yun, Finnegan, Michelle, Severt, Lawrence, Trugman, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004213/
https://www.ncbi.nlm.nih.gov/pubmed/31913519
http://dx.doi.org/10.1111/head.13682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004213/
https://www.ncbi.nlm.nih.gov/pubmed/31913519
http://dx.doi.org/10.1111/head.13682

Ejemplares similares